Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Active Surveillance vs Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Negative Intermediate-Risk NMIBC
NCT07749924Recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Aug 2026
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
Randomised, open-label trial in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by The Second Hospital of Tianjin Medical University. Primary endpoint: Recurrence-free survival at 24 months. Started Aug 2026; status: recruiting.
02
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07749924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07749924.